Skip to main content

Day: March 7, 2023

BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45

Written by Customer Service on . Posted in Public Companies.

FeraMAX Pd Maintenance 45 FeraMAX Pd Maintenance 45MISSISSAUGA, Ontario, March 07, 2023 (GLOBE NEWSWIRE) — On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd Maintenance 45 is BioSyent’s third product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system. The FeraMAX® Pd family of products continues the innovation history of FeraMAX® and strengthens BioSyent’s commitment to women’s health and the management of iron health across various life stages. Iron deficiency disproportionally affects women and children and is an independent risk factor for decreased quality of life and increased morbidity and mortality.i “My personal...

Continue reading

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

Written by Customer Service on . Posted in Public Companies.

FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study’s primary objectives Plasma concentrations within the potential therapeutic dose range were consistent with efficacious exposure levels established in nonclinical disease models and support once-daily oral dosing Reduction in disease-relevant cytokines was observed in exploratory ex-vivo LPS-stimulated whole blood pharmacodynamic assays Topline results support the continued development of FRTX-02 as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Evaluating strategic options to further develop FRTX-02 and maximize shareholder value BOULDER, Colo., March 07, 2023 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX),...

Continue reading

Miromatrix Medical Inc. Announces Proposed Public Offering of Common Stock

Written by Customer Service on . Posted in Public Companies.

EDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Miromatrix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by Miromatrix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual...

Continue reading

Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 3:20 pm ET, as well as 1×1 meetings. To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days. About Chinook Therapeutics, Inc.Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases....

Continue reading

Blue Line Protection Group Appoints new Director

Written by Customer Service on . Posted in Public Companies.

Denver, CO, March 07, 2023 (GLOBE NEWSWIRE) — Dan Allen, Chief Executive Officer of Blue Line Protection Group (OTCQB: BLPG), is pleased to announce the appointment of Andrew Berman as a Director. “Andrew is a versatile executive with a unique background and skill set. He has extensive cannabis experience, including being CEO of Harborside Inc. (CA), which he took public on the Canadian Securities Exchange in 2019, as well as cannabis start-up operations in Hawaii and Ohio. Andrew also has broad government relations experience having served two terms as Mayor for the City of Mill Valley, California. We are looking forward to having him on our board.” Andrew states “I am very excited to be joining the Board of Blue Line Protection Group. This is a unique opportunity to work with a business that has now expanded...

Continue reading

Toll Brothers Announces New Luxury Home Community Coming Soon to Florida’s West Coast

Written by Customer Service on . Posted in Public Companies.

Monterey at Lakewood Ranch will open for sales in summer 2023Monterey at Lakewood Ranch by Toll Brothers Toll Brothers announced its newest luxury home community, Monterey at Lakewood Ranch in Lakewood Ranch, Florida, opening in summer 2023.Monterey at Lakewood Ranch by Toll Brothers “With floor plans designed for today’s buyers and unrivaled personalization options offered on-site, Monterey at Lakewood Ranch will offer residents the best in luxury living in one of Sarasota County’s most desirable communities,”said Brian O’Hara, Division President of Toll Brothers in Tampa/Sarasota.LAKEWOOD RANCH, Fla., March 07, 2023 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community of luxury homes, Monterey at Lakewood Ranch, is coming soon to the desirable...

Continue reading

BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting

Written by Customer Service on . Posted in Public Companies.

BICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma Concentrations BICX104 Subjects Experienced Better 84-Day Treatment Adherence Than Vivitrol® Subjects Company Seeking FDA Approval for Immediate Expanded Access “Compassionate Use” of BICX104 for Over 10 Million Americans with Opioid Use Disorder BioCorRx Applying for Fast Track Designation and Also Seeking FDA Pre-NDA Meeting to Confirm Final Pathway for Regulatory ApprovalANAHEIM, CA, March 07, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB:  BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance use and related disorders, has announced interim positive safety and pharmacokinetic (PK) results for the Phase I clinical trial of the Company’s...

Continue reading

Ebix Hosts Q4 Investor Call Wednesday, March 15, 2023 at 11:00 a.m. ET

Written by Customer Service on . Posted in Public Companies.

JOHNS CREEK, Ga., March 07, 2023 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, financial services, travel, healthcare and e-learning industries, today announced that the Company will report its 2022 fourth quarter and full year results on Wednesday, March 15, 2023, and will host an investor conference call at 11:00 am ET on the same day to discuss the Company’s performance. The call is open to the public. Conference Call, Webcast and Replay Details:Call Date/Time: March 15, 2023 at 11:00 a.m. ET   US & Canada Toll Free: +1 (800) 715-9871   Call ID: # 2396483   Audio Webcast: https://edge.media-server.com/mmc/p/kodfrx33   Replay URL: https://www.ebix.com/investorhomeAbout Ebix, Inc.With approximately...

Continue reading

Tek84 Inc. Announces Acquisition of IDSS Corp.

Written by Customer Service on . Posted in Mergers And Acquisitions.

Combination Expands Tek84’s High Technology X-ray Security Scanning Solutions SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) — High technology security screening and surveillance pioneer Tek84 Inc. announced today the acquisition of Integrated Defense and Security Solutions (IDSS) Corp., a global leader in airport scanner technology. Financial terms were not disclosed. Tek84 develops and manufactures ultra-low-dose x-ray scanning solutions that detect threats – weapons, drugs and other contraband – hidden under clothing, within body cavities and inside vehicles, packages, walls and objects. Tek84 systems are deployed worldwide in jails, prisons and other detention centers, airports, embassies, court houses, border crossings, event venues and critical infrastructure. IDSS combines advanced AI algorithms and high resolution, three-dimensional...

Continue reading

Van Lanschot Kempen promoted to the AMX index and included in the AEX ESG index

Written by Customer Service on . Posted in Public Companies.

Amsterdam/’s-Hertogenbosch in the Netherlands, 7 March 2023 Van Lanschot Kempen will enter the Euronext AMX index and the AEX ESG index as of March 17, 2023 COB. Jeroen Kroes, Chief Financial Officer Van Lanschot Kempen: “The inclusion in both the Midkap index and the AEX ESG index underlines the growth achieved by Van Lanschot Kempen in recent years and our sustainable profile. This will further strengthen our visibility towards investors and is expected to increase liquidity in our stock. At the same time our focus remains unchanged: providing unique, personalised services to our clients. Strategically, we remain focused on sustainable profitable growth, both organically and through acquisitions, with a capital-light balance sheet.” The composition of the Midkap index is reviewed annually in March by Euronext Amsterdam on the basis of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.